Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We investigated the efficacy of cetuximab plus irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer and sought associations between the mutation status of the KRAS gene in tumors and clinical response to cetuximab. METHODS: We randomly assigned patients with epidermal growth factor receptor-positive colorectal cancer with unresectable metastases to receive FOLFIRI either alone or in combination with cetuximab. The primary end point was progression-free survival. RESULTS: A total of 599 patients received cetuximab plus FOLFIRI, and 599 received FOLFIRI alone. The hazard ratio for progression-free survival in the cetuximab-FOLFIRI group as compared with the FOLFIRI group was 0.85 (95% confidence interval [CI], 0.72 to 0.99; P=0.048). There was no significant difference in the overall survival between the two treatment groups (hazard ratio, 0.93; 95% CI, 0.81 to 1.07; P=0.31). There was a significant interaction between treatment group and KRAS mutation status for tumor response (P=0.03) but not for progression-free survival (P=0.07) or overall survival (P=0.44). The hazard ratio for progression-free survival among patients with wild-type-KRAS tumors was 0.68 (95% CI, 0.50 to 0.94), in favor of the cetuximab-FOLFIRI group. The following grade 3 or 4 adverse events were more frequent with cetuximab plus FOLFIRI than with FOLFIRI alone: skin reactions (which were grade 3 only) (in 19.7% vs. 0.2% of patients, P<0.001), infusion-related reactions (in 2.5% vs. 0%, P<0.001), and diarrhea (in 15.7% vs. 10.5%, P=0.008). CONCLUSIONS: First-line treatment with cetuximab plus FOLFIRI, as compared with FOLFIRI alone, reduced the risk of progression of metastatic colorectal cancer. The benefit of cetuximab was limited to patients with KRAS wild-type tumors. (ClinicalTrials.gov number, NCT00154102.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Sub-analysis revealed that the benefits of cetuximab were limited to patients with KRAS wild-type (wt) tumors.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [16]
In the citing paper
“The results of this trial demonstrated a decrease in progression-free survival but no difference in overall survival.”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [16]
In the citing paper
“Some large clinical trials have shown that FOLFIRI (leucovorin + 5-FU + irinotecan) or FOLFOX regimens combined with EGFR inhibitors can benefit KRAS-WT CRC.”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [150]
In the citing paper
“However, CRC with KRAS mutations do not benefit from EGFR inhibitors, possibly because activation of KRAS does not depend upstream on EGFR [149,150,151,152].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [150]
In the citing paper
“According to the CRYSTAL trial, the application of cetuximab and FOLFIRI in first-line treatment can reduce the risk of progression by 15% and increase overall survival (OS) by 8.2 months in patients who have KRAS WT mCRC compared with patients taking FOLFIRI alone [5].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [5]
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Statistical Methods for Rates and Proportions, 2nd ed
GROVE, W. A. (1981) · American Journal of Psychiatry · doi:10.1176/ajp.138.12.1644-a · Cited by 3,748
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256
Self-citationWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Research works printed but not linked: 3
- Rougier P, 2004, J Clin Oncol, 22, 248s, 10.1200/jco.2004.22.14_suppl.3513 · doi:10.1200/jco.2004.22.14_suppl.3513
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Schilsky RL, 2002, Clin Cancer Res, 8, 935
Cited by
Items 301–400 of 1,017
Okines, A. F. C., Ashley, S. E., Cunningham, D., Oates, J. R., Turner, A., Webb, J., Saffery, C., Chua, Y. J., & Chau, I. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.2847 · Cited by 132
Gay, L., Baker, A.-M., & Graham, T. A. (2016) · F1000Research · doi:10.12688/f1000research.7210.1 · Cited by 125
The Liver-First Approach to the Management of Colorectal Cancer With Synchronous Hepatic Metastases
Jegatheeswaran, S., Mason, J. M., Hancock, H. C., & Siriwardena, A. K. (2013) · JAMA Surgery · doi:10.1001/jamasurg.2013.1216 · Cited by 124
“Mentha et al,14 2008 35 13/17a NA 6 (1-21) NA”
Moehler, M. H., Mueller, A., Trarbach, T., Lordick, F., Seufferlein, T. T. W., Kubicka, S., Geißler, M., Schwarz, S., Galle, P. R., & Kanzler, S. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq591 · Cited by 124
“Cetuximab, an immunoglobulin G1 monoclonal antibody that targets the epidermal growth factor receptor (EGFR) 1 has demonstrated efficacy in combination with irinotecan-based therapies in patients with metastatic colorectal cancer (mCRC), particularly in patients with KRAS wild-type tumors [15].”
BackgroundTang, W., Ren, L., Liu, T., Ye, Q., Wei, Y., He, G., Lin, Q., Wang, X., Wang, M., Liang, F., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00174 · Cited by 132
Rethinking the metastatic cascade as a therapeutic target
Mina, L. A., & Sledge, G. W. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.59 · Cited by 137
“Similarly, the anti-EGFR agent cetuximab improves survival in patients with metastatic colorectal cancer yet fails to improve disease-free survival in the setting of micrometastatic disease”
BackgroundTournigand, C., Chibaudel, B., Samson, B., Scheithauer, W., Vernerey, D., Mésange, P., Lledo, G., Viret, F., Ramée, J., Tubiana-Mathieu, N., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00216-8 · Cited by 137
Tosi, F., Magni, E., Amatu, A., Mauri, G., Bencardino, K. B., Truini, M., Veronese, S. M., Carlis, L. G. D., Ferrari, G. C., Nichelatti, M., et al. (2017) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2017.01.004 · Cited by 137
Cherny, N. I., de Vries, E. G. E., Dafni, U. G., Garrett-Mayer, E. S., McKernin, S. E., Piccart, M. J., Latino, N. J., Douillard, J.-Y., Schnipper, L. E., Somerfield, M. R., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00729 · Cited by 129
Smart nanocarriers-based drug delivery for cancer therapy: An innovative and developing strategy
Huda, S., Alam, A., & Sharma, P. K. (2020) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2020.102018 · Cited by 127
Parseghian, C. M., Napolitano, S., Loree, J. M., & Kopetz, S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0823 · Cited by 121
“(6-9) The KRAS mutation was initially identified in codons 12 and 13 of exon 2 which result in constitutive activation of the RAS-RAFMEK-ERK (MAPK) pathway.(8-11) Activating mutations in KRAS are detected in approximately 40% of mCRC,(2,3) with good concordance between primary tumors and distant metastases.”
BackgroundDendrimer nanoparticles for colorectal cancer applications
Carvalho, M. R., Reis, R. L., & Oliveira, J. M. (2020) · Journal of Materials Chemistry B · doi:10.1039/c9tb02289a · Cited by 136
Treatment of Unresectable and Metastatic Cutaneous Squamous Cell Carcinoma
Cranmer, L. D., Engelhardt, C., & Morgan, S. S. (2010) · The Oncologist · doi:10.1634/theoncologist.2009-0210 · Cited by 134
Chemotherapy Before Liver Resection of Colorectal Metastases: Friend or Foe?
Lehmann, K., Rickenbacher, A., Weber, A., Pestalozzi, B. C., & Clavien, P. (2011) · Annals of Surgery · doi:10.1097/sla.0b013e3182356236 · Cited by 142
Pak, L. M., Kemeny, N. E., Capanu, M., Chou, J. F., Boucher, T., Cercek, A., Balachandran, V. P., Kingham, T. P., Allen, P. J., DeMatteo, R. P., et al. (2018) · Journal of Surgical Oncology · doi:10.1002/jso.24898 · Cited by 119
A concise review on cancer treatment methods and delivery systems
Bidram, E., Esmaeili, Y., Ranji‐Burachaloo, H., Al-Zaubai, N., Zarrabi, A., Stewart, A. G., & Dunstan, D. E. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.101350 · Cited by 140
Li, Q.-H., Wang, Y.-Z., Tu, J., Liu, C.-W., Yuan, Y.-J., Lin, R., He, W.-L., Cai, S.-R., He, Y.-L., & Ye, J.-N. (2020) · Gastroenterology Report · doi:10.1093/gastro/goaa026 · Cited by 119
Antibody-Mediated Delivery of Anti– KRAS -siRNA In Vivo Overcomes Therapy Resistance in Colon Cancer
Bäumer, S., Bäumer, N., Appel, N., Terheyden, L., Fremerey, J., Schelhaas, S., Wardelmann, E., Buchholz, F., Berdel, W. E., & Müller-Tidow, C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2017 · Cited by 119
Pinto, C., Barone, C. A., Girolomoni, G., Russi, E. G., Merlano, M. C., Ferrari, D., & Maiello, E. (2011) · The Oncologist · doi:10.1634/theoncologist.2010-0298 · Cited by 129
HDAC Inhibition Decreases the Expression of EGFR in Colorectal Cancer Cells
Chou, C., Wu, M., Huang, W., & Chen, C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018087 · Cited by 130
Genomic Medicine Frontier in Human Solid Tumors: Prospects and Challenges
Dienstmann, R., Rodon, J., Barretina, J., & Tabernero, J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2268 · Cited by 117
Petrelli, F., Borgonovo, K., & Barni, S. (2013) · Targeted Oncology · doi:10.1007/s11523-013-0257-x · Cited by 132
Targeted therapy in metastatic colorectal cancer – An example of personalised medicine in action
Heinemann, V., Douillard, J. Y., Ducreux, M., & Peeters, M. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.12.011 · Cited by 120
Gerdes, C. A., Nicolini, V. G., Herter, S., van Puijenbroek, E., Lang, S., Roemmele, M., Moessner, E., Freytag, O., Friess, T., Ries, C. H., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0989 · Cited by 118
Oncogenic mutations as predictive factors in colorectal cancer
Lièvre, A., Blons, H., & Laurent-Puig, P. (2010) · Oncogene · doi:10.1038/onc.2010.89 · Cited by 117
Virostko, J. M., Capasso, A., Yankeelov, T. E., & Goodgame, B. W. (2019) · Cancer · doi:10.1002/cncr.32347 · Cited by 134
Karoui, M., Roudot‐Thoraval, F., Mesli, F., Mitry, E., Aparicio, T., Guetz, G. D., Louvet, C., Landi, B., Tiret, E., & Sobhani, I. (2011) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0b013e31821cced0 · Cited by 116
“– 6 Moreover, this decision must now take into account the recent advances, in particular, angiogenic or anti-EGFR drugs that have been shown to improve response rates and survival, resulting in a higher proportion of patients with metastatic colorectal cancer suitable for curative resection.(15,16) However, the benef…”
BackgroundResultGatzemeier, U., von Pawel, J., Vynnychenko, I. O., Zatloukal, P., de Marinis, F., Eberhardt, W., Paz-Ares, L. G., Schumacher, K.-M., Goddemeier, T., O'Byrne, K. J., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70278-3 · Cited by 120
Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer
Chan, D. L. H., Segelov, E., Wong, R. S., Smith, A., Herbertson, R. A., Li, B. T., Tebbutt, N., Price, T., & Pavlakis, N. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007047.pub2 · Cited by 114
Ciardiello, F., Normanno, N., Maiello, E., Martinelli, E., Troiani, T., Pisconti, S., Giuliani, F., Barone, C., Cartenì, G., Rachiglio, A. M., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu230 · Cited by 116
“The results of the CAPRI-GOIM trial confirmed the efficacy of the first-line combination of FOLFIRI plus cetuximab in KRAS exon 2 wild-type mCRC patients as previously reported [1, 12].”
ResultMoris, D., Ronnekleiv‐Kelly, S. M., Kostakis, I. D., Tsilimigras, D. I., Beal, E. W., Papalampros, A., Dimitroulis, D., Felekouras, E. S., & Pawlik, T. M. (2017) · World Journal of Surgery · doi:10.1007/s00268-017-4181-6 · Cited by 122
Hecht, J. R., Cohn, A. L., Dakhil, S. R., Saleh, M. N., Piperdi, B., Cline-Burkhardt, M., Tian, Y., & Go, W. Y. (2015) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2014.12.009 · Cited by 128
Balancing the efficacy and toxicity of chemotherapy in colorectal cancer
Braun, M. S., & Seymour, M. T. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834010388342 · Cited by 100
Molecular Biomarkers in the Personalized Treatment of Colorectal Cancer
Sinicrope, F. A., Okamoto, K., Kasi, P. M., & Kawakami, H. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2016.02.008 · Cited by 116
Biomarkers in Pancreatic Cancer: Diagnostic, Prognostic, and Predictive
Fong, Z. V., & Winter, J. M. (2012) · The Cancer Journal · doi:10.1097/ppo.0b013e31827654ea · Cited by 116
“For instance, KRAS sequencing is routinely performed in patients with metastatic colorectal cancer to select patients for anti-EGFR therapy.(6) Similarly, microsatellite stability helps predict responsiveness to 5-fluorouracil.”
BackgroundBe Active or Not: the Relative Contribution of Active and Passive Tumor Targeting of Nanomaterials
Li, R., Zheng, K., Yuan, C., Chen, Z., & Huang, M. (2017) · Nanotheranostics · doi:10.7150/ntno.19380 · Cited by 123
“Monoclonal anti-EGFR antibodies (mAbs) cetuximab [107-110] and panitumumab [111, 112] are both approved by the FDA, originally for metastatic colorectal cancer.”
BackgroundEndris, V., Penzel, R., Warth, A., Muckenhuber, A., Schirmacher, P., Stenzinger, A., & Weichert, W. (2013) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.06.002 · Cited by 113
Dunne, P. D., McArt, D. G., Blayney, J. K., Kalimutho, M., Greer, S., Wang, T., Srivastava, S., Ong, C. W., Arthur, K., Loughrey, M. B., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1354 · Cited by 123
Pietrantonio, F., Morano, F., Corallo, S., Miceli, R., Lonardi, S., Raimondi, A., Cremolini, C., Rimassa, L., Bergamo, F., Sartore-Bianchi, A., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1467 · Cited by 113
“117 (0) 96 (4) 73 (6) 50 (12) 14 (26) 7 (29) 105 (3)”
Integrated approaches for precision oncology in colorectal cancer: The more you know, the better
Andrei, P., Battuello, P., Grasso, G., Rovera, E., Tesio, N., & Bardelli, A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.04.007 · Cited by 113
A systematic review of treatment guidelines for metastatic colorectal cancer
Edwards, M., Chadda, S., Zhao, Z., Barber, B., & Sykes, D. (2011) · Colorectal Disease · doi:10.1111/j.1463-1318.2011.02765.x · Cited by 141
Circulating Tumor Cells in Colorectal Cancer: Past, Present, and Future Challenges
Negin, B. P., & Cohen, S. J. (2010) · Current Treatment Options in Oncology · doi:10.1007/s11864-010-0115-3 · Cited by 118
“In mCRC for example, KRAS mutations predict for response to anti-EGFR antibody therapy [5, 6, 47].”
BackgroundAndrès, A., Toso, C., Adam, R. A., Barroso, E., Hubert, C., Capussotti, L., Gerstel, E., Roth, A. D., Majno, P. E., & Mentha, G. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e3182734423 · Cited by 119
“Centers that registered the majority of the patients (≥10 per center) for this study were Hôpital Paul Brousse-Centre hépatobiliaire, Paris, France (102 patients), Centro Hepato-bilio-pancreatico e de Transplantacao do Hospital de Curry Cabral, Lisbon, Portugal (64), UCL St Luc, Brussels, Belgium (53), Ospedale Mauriz…”
BackgroundMoosmann, N., von Weikersthal, L. F., Vehling‐Kaiser, U., Stauch, M. B., Hass, H. G., Dietzfelbinger, H., Oruzio, D. V., Klein, S., Zellmann, K., Decker, T. W., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.1936 · Cited by 126
Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial
Ocvirk, J., Brodowicz, T., Wrba, F., Ciuleanu, T., Kurteva, G. P., Beslija, S., Koza, I., Pápai, Z., Messinger, D., Yılmaz, U., et al. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i25.3133 · Cited by 120
Cremolini, C., Antoniotti, C., Lonardi, S., Aprile, G., Bergamo, F., Masi, G., Grande, R., Tonini, G., Mescoli, C., Cardellino, G. G., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5314 · Cited by 127
“Such modification has been adopted given previous reports of a mild increase in grade 3-4 diarrhea when anti-EGFR antibodies are combined with chemotherapy, especially for irinotecan-based doublets (31, 63) or triplets (34, 35).”
BackgroundResultInfluentialTargeted therapy for hepatocellular carcinoma
Spangenberg, H. C., Thimme, R., & Blum, H. E. (2009) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2009.86 · Cited by 125
“On the basis of randomized, clinical studies, several targeted therapies have now been licensed for clinical use and comprise part of the first-line treatment for patients with various malignancies, including colorectal cancer”
BackgroundSaridaki, Z., Papadatos-Pastos, D., Tzardi, M. N., Mavroudis, D., Bairaktari, E. T., Arvanity, H., Stathopoulos, E. N., Georgoulias, V., & Souglakos, J. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605694 · Cited by 117
“…primary tumour is now mandatory for the treatment of metastatic disease, as it is a predictor of resistance to monoclonal antibodies of the epidermal growth factor receptor (anti-EGFR moAbs) (Bokemeyer et al, 2008; Douillard et al, 2009; Hecht et al, 2009; Tol et al, 2009; Van Cutsem et al, 2009).”
BackgroundTreatment in advanced colorectal cancer: what, when and how?
Chau, I., & Cunningham, D. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605061 · Cited by 121
“Table 5 shows the results of these studies (Amado et al, 2008; Karapetis et al, 2008; Tejpar et al, 2008; Van Cutsem et al, 2009; Bokemeyer et al, 2009; Hecht et al, 2009; Tol et al, 2009).”
BackgroundInfluentialPentheroudakis, G., Kotoula, V., De Roock, W., Kouvatseas, G., Papakostas, P., Makatsoris, T., Papamichael, D., Xanthakis, I., Sgouros, J., Televantou, D., et al. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-49 · Cited by 111
Self-citationFranklin, W. A., Haney, J., Sugita, M., Bemis, L., Jimeno, A., & Messersmith, W. A. (2009) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2010.080131 · Cited by 111
Do, H., Wong, S. Q., Li, J., & Dobrovic, A. (2013) · Clinical Chemistry · doi:10.1373/clinchem.2012.202390 · Cited by 128
Dejmek, A., Zendehrokh, N., Tomaszewska, M., & Edsjö, A. (2013) · Cancer Cytopathology · doi:10.1002/cncy.21276 · Cited by 116
Strategies for modern biomarker and drug development in oncology
Smith, A. D., Roda, D., & Yap, T. A. (2014) · Journal of Hematology & Oncology · doi:10.1186/s13045-014-0070-8 · Cited by 116
“Despite this being a retrospective subgroup analysis, p16 status appears to be a relevant biomarker for patients with SCCHN, and should be explored prospectively in the future [101].”
BackgroundInfluentialStintzing, S., von Weikersthal, L. F., Decker, T. W., Vehling‐Kaiser, U., Jäger, E., Heintges, T., Stoll, C. G., Giessen, C. A., Modest, D. P., Neumann, J. H. L., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr571 · Cited by 114
“Both agents have manageable toxicity profiles and were able to improve treatment efficacy [1–3].”
BackgroundMethodRizzo, A., Frega, G., Ricci, A. D., Palloni, A., Abbati, F., Lorenzo, S. D., Deserti, M., Tavolari, S., & Brandi, G. (2020) · In Vivo · doi:10.21873/invivo.11798 · Cited by 114
Lessons From the Adjuvant Bevacizumab Trial on Colon Cancer: What Next?
Van Cutsem, E., Lambrechts, D., Prenen, H., Jain, R. K., & Carmeliet, P. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2701 · Cited by 113
Tabernero, J., Cervantes, A., Rivera, F., Martinelli, E., Rojo, F., von Heydebreck, A., Macarulla, T., Rodriguez-Braun, E., Eugenia Vega-Villegas, M., Senger, S., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6043 · Cited by 110
Self-citationTougeron, D., Lecomte, T., Pagès, J., Villalva, C., Collin, C., Ferru, A., Tourani, J. M., Silvain, C., Levillain, P., & Karayan, L. (2013) · Annals of Oncology · doi:10.1093/annonc/mds620 · Cited by 132
“Over recent decades, clinical trials have shown the benefit of adding anti-EGFR (epidermal growth factor receptor) or anti-VEGF (vascular endothelial growth factor) Mabs to chemotherapy in the treatment of mCRC [2–4].”
BackgroundInfluentialFojo, T., & Parkinson, D. R. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1277 · Cited by 110
The heterogeneous clinical and pathological landscapes of metastatic Braf-mutated colorectal cancer
Fanelli, G. N., Pozzo, C. A. D., Depetris, I., Schirripa, M., Brignola, S., Biason, P., Balistreri, M., Santo, L. D., Lonardi, S., Munari, G., et al. (2020) · Cancer Cell International · doi:10.1186/s12935-020-1117-2 · Cited by 129
de Oliveira, R. L., Hamm, A., & Mazzone, M. (2011) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.04.001 · Cited by 133
Tsukihara, H., Nakagawa, F., Sakamoto, K., Ishida, K., Tanaka, N., Okabe, H., Uchida, J., Matsuo, K., & Takechi, T. (2015) · Oncology Reports · doi:10.3892/or.2015.3876 · Cited by 109
“bevacizumab and cetuximab or panitumumab are key drugs in colorectal cancer treatment, used either alone or in combination with other chemotherapies (3-5,18-21).”
BackgroundBlons, H., Emile, J. F., Le Malicot, K., Julié, C., Zaanan, A., Tabernero, J., Mini, E., Folprecht, G., Van Laethem, J. L., Thaler, J., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu464 · Cited by 108
Self-citationChemotherapy Usage Patterns in a US-Wide Cohort of Patients With Metastatic Colorectal Cancer
Abrams, T. A., Meyer, G. E., Schrag, D., Meyerhardt, J. A., Moloney, J., & Fuchs, C. S. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt371 · Cited by 111
Pahl, J. H. W., Ruslan, S. E. N., Buddingh, E. P., Santos, S. J., Szuhai, K., Serra, M., Gelderblom, H., Hogendoorn, P. C. W., Egeler, R. M., Schilham, M. W., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2277 · Cited by 109
Voigt, M., Braig, F., Göthel, M., Schulte, A., Lamszus, K., Bokemeyer, C., & Binder, M. (2012) · Neoplasia · doi:10.1593/neo.121242 · Cited by 106
“Of these, KRAS is the only biomarker currently used in daily practice to select patients with metastatic colorectal cancer for anti–EGFR-targeted treatment.”
BackgroundMarcuello, E., Páez, D., Paré, L., Salazar, J., Sebio, A., del Río, E., & Baiget, M. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.206 · Cited by 112
“This scenario has improved even more with the recent introduction of new biological drugs such as bevacizumab or cetuximab in the treatment schemes (Hurwitz et al, 2004; Van Cutsem et al, 2009).”
BackgroundMao, C., Wu, X.-Y., Yang, Z.-Y., Threapleton, D. E., Yuan, J.-Q., Yu, Y.-Y., & Tang, J.-L. (2015) · Scientific Reports · doi:10.1038/srep08065 · Cited by 107
Vecchione, L., Jacobs, B., Normanno, N., Ciardiello, F., & Tejpar, S. (2011) · Experimental Cell Research · doi:10.1016/j.yexcr.2011.08.021 · Cited by 119
Self-citationKRAS Mutation Testing in Colorectal Cancer
Plesec, T. P., & Hunt, J. L. (2009) · Advances in Anatomic Pathology · doi:10.1097/pap.0b013e3181a9d4ed · Cited by 115
“The final series showed a trend toward a survival advantage in KRAS wild type tumors, but statistical calculations were not performed.(37) These trials have shown that up to 40% of patients with KRAS wild type colorectal cancer show at least a partial response to anti-EGFR therapy, an improvement over the 10% before K…”
MethodImproving prospects for targeting RAS
Singh, H., Longo, D. L., & Chabner, B. A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1052 · Cited by 107
Azzopardi, N., Lecomte, T., Ternant, D., Boisdron-Celle, M., Piller, F., Morel, A., Gouilleux‐Gruart, V., Desvignes, C., Watier, H., Gamelin, E. C., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1081 · Cited by 119
Kawazoe, A., Shitara, K., Fukuoka, S., Kuboki, Y., Bando, H., Okamoto, W., Kojima, T., Fuse, N., Yamanaka, T., Doi, T., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1276-z · Cited by 106
“These mutations are validated biomarkers for resistance to anti-epidermal growth factor receptor (EGFR) therapy in patients with mCRC [6-11].”
BackgroundCancer immunotherapy: Strategies for personalization and combinatorial approaches
Sathyanarayanan, V., & Neelapu, S. S. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.10.009 · Cited by 126
A theranostic micelleplex co-delivering SN-38 and VEGF siRNA for colorectal cancer therapy
Lee, S., Yang, C., Peng, C., Wei, M., Chen, K.-C., Yao, C.-J., & Shieh, M. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.01.068 · Cited by 111
A Third Shot at EGFR: New Opportunities in Cancer Therapy
Guardiola, S., Varese, M., Sánchez‐Navarro, M., & Giralt, E. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.10.004 · Cited by 113
Sorafenib: Where Do We Go from Here?
Siegel, A. B., Olsen, S. K., Magun, A. M., & Brown, R. S. (2010) · Hepatology · doi:10.1002/hep.23633 · Cited by 114
Peptide-based targeting strategies for simultaneous imaging and therapy with nanovectors
Accardo, A., Tesauro, D., & Morelli, G. (2013) · Polymer Journal · doi:10.1038/pj.2012.215 · Cited by 114
Mucinous epithelial ovarian carcinoma
Perren, T. J. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw087 · Cited by 122
“EGFR-targeted monoclonal antibody treatment such as cetuximab or panitumumab is effective for improving response rate and duration of response in the first-line treatment of metastatic colorectal carcinoma in patients where there is EGFR expression and where the tumour is KRAS wild-type [39] and as a result is now lic…”
BackgroundZhai, Z., Yu, X., Yang, B. J., Zhang, Y., Zhang, L., Li, X., & Sun, H. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.08.033 · Cited by 119
Miyamoto, Y., Suyama, K., & Baba, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040752 · Cited by 106
“The phase III CALGB/SWOG 80405 trial [42] could not demonstrate a benefit for initial cetuximab versus bevacizumab in combination with either FOLFIRI or FOLFOX, even in patients with only wild-type RAS tumors.”
BackgroundInfluentialSchneider, M. A., Eden, J., Pache, B. C.-E., Laminger, F., López‐López, V., Steffen, T., Hübner, M., Kober, F., Roka, R., Campos, P. C., et al. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002899 · Cited by 111
Lu, L., Dercle, L., Zhao, B., & Schwartz, L. H. (2021) · Nature Communications · doi:10.1038/s41467-021-26990-6 · Cited by 104
Quan, D., Gallinger, S., Nhan, C., Auer, R. C., Biagi, J. J., Fletcher, G. G., Law, C., Moulton, C.-A. E., Ruo, L., Wei, A. C.-C., et al. (2012) · Surgery · doi:10.1016/j.surg.2011.12.018 · Cited by 115
Mise, Y., Zimmitti, G., Shindoh, J., Kopetz, S., Loyer, E. M., Andreou, A., Cooper, A. B., Kaur, H., Aloia, T. A., Maru, D. M., et al. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4042-6 · Cited by 109
“metastatic colorectal cancer and patients with metastases limited to the liver.(16,18,29) Additionally, a growing body of evidence suggests that the RAS mutational status of CLM might be associated with tumor aggressiveness.”
BackgroundKirstein, M. M., Lange, A., Prenzler, A., Manns, M. P., Kubicka, S., & Vogel, A. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0032 · Cited by 112
Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours
Crucitta, S., Cucchiara, F., Mathijssen, R. H. J., Mateo, J., Jager, A., Joosse, A., Passaro, A., Attili, I., Petrini, I., van Schaik, R. H., et al. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102340 · Cited by 115
Advances in the management of colorectal cancer: from biology to treatment
Ahmed, S., JOHNSON, K., Ahmed, O., & Iqbal, N. (2014) · International Journal of Colorectal Disease · doi:10.1007/s00384-014-1928-5 · Cited by 117
“5 months compared with 20 months with FOLFIRI alone [109].”
Kawada, K., Nakamoto, Y., Kawada, M., Hida, K., Matsumoto, T., Murakami, T., Hasegawa, S., Togashi, K., & Sakai, Y. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1909 · Cited by 104
“presence of wild-type KRAS gene does not guarantee the response to anti-EGFRmonoclonal antibodies, a number of large studies have shown that cetuximab has significant efficacy in treatment of patients with metastatic CRC with wild-type KRAS tumors (25, 26).”
Molecular Alterations and Biomarkers in Colorectal Cancer
Grady, W. M., & Pritchard, C. C. (2014) · Toxicologic Pathology · doi:10.1177/0192623313505155 · Cited by 104
“Results of 4 large phase III randomized have established unequivocally that metastatic CRC patients with KRAS mutations in codon 12 or 13 do not benefit from cetuximab or panitumumab therapy (Amado et al. 2008; Bokemeyer et al. 2009; Karapetis et al. 2008; Van Cutsem et al. 2007).”
BackgroundTherapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence
Troiani, T., Napolitano, S., Della Corte, C. M., Martini, G., Martinelli, E., Morgillo, F., & Ciardiello, F. (2016) · ESMO Open · doi:10.1136/esmoopen-2016-000088 · Cited by 104
Effect of Simvastatin on Cetuximab Resistance in Human Colorectal Cancer With KRAS Mutations
Lee, J., Lee, I., Han, B., Park, J. O., Jang, J., Park, C., & Kang, W. K. (2011) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djr070 · Cited by 103
Angulo, B., García-García, E., Martínez, R., Suárez‐Gauthier, A., Conde, E., Hidalgo, M. M., & López‐Ríos, F. (2010) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2010.090139 · Cited by 110
“Paradoxically, given the low sensitivity of direct sequencing, none of these methods has replaced it as the gold standard for the characterization of somatic mutations in tumors.(4,8,19,25,26) This is particularly relevant if we bear in mind the events associated with the methods to determine other predictive markers.”
BackgroundKRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy
Gaedcke, J., Grade, M., Jung, K., Schirmer, M., Jo, P., Obermeyer, C., Wolff, H. A., Herrmann, M. K. A., Beißbarth, T., Becker, H., et al. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.10.001 · Cited by 110
“KRAS mutations influence therapeutic outcome in patients treated with anti-EGFR agents [4,5,26,27] and potentially mediate resistance to ionizing radiation [28,29].”
Prognostic and predictive response factors in colorectal cancer patients: Between hope and reality
Divitiis, C. D., Nasti, G., Montano, M., Fisichella, R., Iaffaioli, R. V., & Berretta, M. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i41.15049 · Cited by 128
Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab
Pander, J., Heusinkveld, M., van der Straaten, T., Jordanova, E. S., Baak-Pablo, R., Gelderblom, H., Morreau, H., van der Burg, S. H., Guchelaar, H.-J., & van Hall, T. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0239 · Cited by 101
“One intriguing question still remains: why does cetuximab mediate anti-tumor effects as a single agent (18, 19), whereas its addition to bevacizumab plus chemo-therapy leads to worse survival? Based on our findings, we speculate that cetuximab induces local release of pro-tumor mediators, amongst which VEGF, and there…”
BackgroundMargonis, G. A., Spolverato, G., Kim, Y., Karagkounis, G., Choti, M. A., & Pawlik, T. M. (2015) · Annals of Surgical Oncology · doi:10.1245/s10434-015-4587-z · Cited by 104
Pelz, J. O. W., Chua, T. C., Esquivel, J., Stojadinovic, A., Doerfer, J., Morris, D. L., Maeder, U., Germer, C.-T., & Kerscher, A. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-689 · Cited by 102
Becquemont, L., Alfirevic, A., Amstutz, U., Brauch, H. B., Jacqz-Aigrain, É., Laurent‐Puig, P., Molina‐Vila, M. Á., Niemi, M., Schwab, M. G., Somogyi, A. A., et al. (2010) · Pharmacogenomics · doi:10.2217/pgs.10.147 · Cited by 116
Metadata
- Authors
- Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., Roh, J. K., Folprecht, G., Ruff, P., Stroh, C., Tejpar, S., Schlichting, M., Nippgen, J., & Rougier, P.
- Affiliations
- Klinikum Oldenburg (DE)
- Moscow City Oncology Hospital №62 (RU)
- Petz Aladár Megyei Oktató Kórház (HU)
- National University Hospital (SG)
- Yonsei University (KR)
- University Hospital Carl Gustav Carus (DE)
- University of the Witwatersrand (ZA)
- Merck KGaA, Darmstadt (Germany) (DE)
- Universitair Ziekenhuis Leuven (BE)
- Hôpital Ambroise-Paré (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2009-04-02
- Volume
- 360
- Issue
- 14
- Pages
- 1408-1417
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2095201384
- Cited by
- 3,877
- References
- 34
- Citations by year
- 2026: 83 · 2025: 87 · 2024: 105 · 2023: 136 · 2022: 169 · 2021: 173 · 2020: 194 · 2019: 199 · 2018: 172 · 2017: 221 · 2016: 275 · 2015: 307 · 2014: 337 · 2013: 328 · 2012: 331
- FWCI
- 179.06
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- cetuximab, FOLFIRI, metastatic colorectal cancer, first-line therapy, KRAS mutation status, epidermal growth factor receptor, progression-free survival, overall survival, treatment response, adverse events, irinotecan, 5-fluorouracil, leucovorin, skin reactions, diarrhea, infusion reactions, anti-EGFR therapy
- MeSH terms
- Cetuximab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Leucovorin, Female, Fluorouracil, Humans, Male, Middle Aged, Mutation, Neoplasm Metastasis, Genes, ras, Colorectal Neoplasms, Disease Progression, Kaplan-Meier Estimate, Young Adult, Antibodies, Monoclonal, Humanized, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.